During the second Emultech Demonstration Day, we launched our new brand. The logo, visual style and website were designed to communicate what we stand for: a professional high tech company, a technology that is dependable, and products that trigger your imagination.
The first Emultech Demonstration Day on Microfluidic Encapsulation was organized in Eindhoven, the Netherlands on 6 April. Over fifty people from industry came along to experience a demonstration of microfluidic encapsulation with the Emultech Lab first hand.
The second Demonstration Day will take place on September 21st, in Oss (The Netherlands).
30 January 2017
The collaboration will combine EmulTech's innovative technology with Avivia's expertise in complex drug reformulation, to deliver solutions for today's increasing request from pharmaceutical companies. Both companies encounter customers with complex product ideas, who are hitting a wall. Whether it being a new product or reformulation product, life cycle management or generics plus. Teaming up with Avivia was a natural step, as EmulTech was looking to strengthen its offering to its customer and Avivia was looking to do the same.
January 12, 2017
Duke MEMS researcher's five-year, $6-million appointment as a Niels Bohr Professor in Odense Denmark creates a vibrant center for research, launches new collaborations back at Duke
EmulTech and Eindhoven University of Technology (TU/e) hosted this year´s 2nd Annual Complex Formulations Symposium September 15th, in Eindhoven, the Netherlands. The event was opened and chaired by Carmen van Vilsteren, director of TU/e Strategic Area Health. The goal of this event was to share advancements of new biological and health related technologies, developments and manufacturing.
January 15, 2016
Ophthalmic drug delivery is a growing field of interest in the drug delivery industry. EmulTech's unique capabilities offer great advantages in the development of ophthalmics!
September 24, 2015
Scale up from single micro droplets to microfluidic scale up production is successful after characterization of single particles to determine the optimal process window.
June 24, 2015
EmulTech offers pharmaceutical companies a unique opportunity in life cycle management of originator drug products by providing a platform for Next Generation Drug Product development.
June 11, 2015
EmulTech's INFINITY platform provides unique process understanding allowing for high reproducibility in development and during scale up.
May 15, 2015
Another undisclosed global ophthalmics company has adopted the INFINITY platform for its drug delivery development program.
March 3, 2015
Drug product developers continue to demand more controlled manufacturing techniques, especially for the most challenging target of drug delivery: the eye. At EmulTech, we experience the growing interest in delivery of active ingredients to the eye, also known as ocular or ophthalmic delivery.
February 4, 2015
The INFINITY platform has a new user! The Oss-based CRO, ChemConnection, added the unique microfluidic platform to its range of capabilities.
January 28, 2015
EmulTech is proud to announce the University of Antwerp acquired the INFINITY system for a four-year research program to push the boundaries in micro-particle based drug delivery research.
April 17, 2014
Microencapsulation is a promising drug delivery technology in which APIs are encapsulated with a natural or synthetic material that targets delivery by controlling the API's release.
October 17, 2013
Microfluidics is recognised as one of the most promising solutions for micro-encapsulation in the pharmaceutical industry, and the micro-channel cross-intersection design is of particular interest.